Compare · GILD vs IPSC
GILD vs IPSC
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Century Therapeutics Inc. (IPSC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and IPSC operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $183.41B, about 734.0x IPSC ($249.9M).
- Over the past year, GILD is up 33.0% and IPSC is up 163.2% - IPSC leads by 130.1 points.
- GILD has been more active in the news (4 items in the past 4 weeks vs 3 for IPSC).
- GILD has more recent analyst coverage (25 ratings vs 14 for IPSC).
- Company
- Gilead Sciences Inc.
- Century Therapeutics Inc.
- Price
- $157.42+2.51%
- $1.50+7.53%
- Market cap
- $183.41B
- $249.9M
- 1M return
- +6.57%
- -20.21%
- 1Y return
- +33.05%
- +163.16%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 14
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Century Therapeutics Inc.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Latest GILD
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
- Chief Medical Officer Berger Dietmar converted options into 533 shares and covered exercise/tax liability with 263 shares, increasing direct ownership by 1% to 19,522 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 1% to 119,684 units (SEC Form 4)
Latest IPSC
- Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
- Century Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
- Officer Russotti Gregory sold $4,993 worth of shares (2,587 units at $1.93), decreasing direct ownership by 0.51% to 509,198 units (SEC Form 4) to satisfy tax liability
- SVP Finance & Operations Carr Douglas sold $3,200 worth of shares (1,658 units at $1.93), decreasing direct ownership by 0.33% to 502,907 units (SEC Form 4) to satisfy withholding obligation
- President and CEO Pfeiffenberger Brent covered exercise/tax liability with 13,850 shares, decreasing direct ownership by 0.38% to 3,633,839 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Truitt Joseph
- SEC Form 3 filed by new insider Truitt Joseph
- President and CEO Pfeiffenberger Brent covered exercise/tax liability with 463 shares, decreasing direct ownership by 0.01% to 3,633,839 units (SEC Form 4) to satisfy tax liability
- SVP Finance & Operations Carr Douglas sold $521 worth of shares (254 units at $2.05), decreasing direct ownership by 0.05% to 504,565 units (SEC Form 4) to cover withholding tax